How Pharmacists Could Be Key to Addressing the Opioid Crisis
Optimal adherence to long-acting injectable buprenorphine (BUP-XR or Sublocade®) for opioid use disorder saves $15,017 per patient annually by drastically reducing costly emergency department visits and detoxification events. This research supports the economic benefits of paying community pharmacists to administer long-acting injections, effectively improving treatment access while lowering overall healthcare spending.
No Payment, No Program: What the 2025 Medicaid Summit Means for Pharmacy-Based OUD Treatment
Establishing a sustainable model for pharmacist-led clinical services requires more than just clinical expertise—it requires a framework for reimbursement. Based on the fundamental pillars of Infrastructure, Collaboration, and Dedicated Time, this guide explores how pharmacists can successfully navigate Medicaid payment structures.
By aligning these three areas, pharmacies can transition from a product-centered model to a service-oriented one that prioritizes patient outcomes and professional sustainability.